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showed favorable results for EBUS-TBNA. A comparison of EBUS-
TBNA with CT and PET has shown favorable results for EBUS-TBNA 
in the lymph node staging of lung cancer 4.
During the assessment of lung tumors, we may come across cases 
where tumors are located adjacent to the bronchus, but inconclusive 
results from conventional bronchoscopic biopsy procedures. CP-EBUS 
can be used for real-time biopsies of tumors adjacent to the airways. 
In our experience in 27 patients with intrapulmonary lung tumors, the 
diagnostic yield was 89%. Conventional bronchoscopy prior to EBUS-
TBNA was non-diagnostic in 22 out of the 27 cases. Cytological and/or 
histological samples were diagnostic in 24 patients. 
Sarcoidosis should be substantiated by pathological means in order 
well to exclude other diseases. The role of EBUS-TBNA in diagnosis 
of sarcoidosis has also been proven to be effective. In 65 patients with 
suspected sarcoidosis with enlarged hilar or mediastinal lymph nodes 
EBUS-TBNA was performed on a total of 77 lymph node station. The 
ﬁnal diagnosis of sarcoidosis was given in 61 patients (93.8%). The 
remaining 4 patients were diagnosed as Wegener’s granulomatosis 
(n=1) or indeﬁnite (n=3). In patients with ﬁnal diagnosis of sarcoidosis, 
EBUS-TBNA demonstrated noncaseating epithelioid cell granulomas 
in 56 patients (91.8%) 5. Ongoing studies are looking at the comparison 
of EBUS-TBNA with other conventional modalities.
EBUS-TBNA is also useful for the assessment of mediastinal tumors. 
Mediastinal cysts are easy to evaluate with EBUS-TBNA. Other medi-
astinal tumors diagnosed by EBUS-TBNA in our department include 
lung cancer, lymphoma, thymic cancer, and mediastinal goiter. Com-
pared to diagnosis of lymph node metastasis in lung cancer patients, cy-
tological diagnosis of mediastinal tumors is often times more difﬁcult. 
Lymphoma seems to be the most challenging among the mediastinal 
tumors. To solve this problem, there is a need for a larger needle which 
will allow a ﬁrm diagnosis by histological specimens.
Although the diagnostic yield of EBUS-TBNA reported up-to-date is 
quite high, there are disadvantages as well. EBUS-TBNA cannot access 
the subaortic and paraesophageal lymph nodes. For the assessment of 
paraesophageal lymph nodes, EUS-FNA is the examination of choice. 
Another disadvantage of EBUS-TBNA is the difﬁculties of the proce-
dure. The direction of view of the scope is 30 degrees forward oblique 
making the manipulation a little difﬁcult. Ten to 20 procedures in the 
hands of an experienced bronchoscopist is probably needed to be able 
to perform EBUS-TBNA smoothly. 
EBUS-TBNA is a novel approach that is safe and has a good diagnostic 
yield. This new ultrasound puncture bronchoscope has an excellent po-
tential in assisting safe and accurate diagnostic interventional bronchos-
copy in respiratory diseases. Further prospective studies describing the 
diagnostic yield of EBUS-TBNA compared to other conventional tools 
will be needed to support the value of this new modality.
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Introduction
During the last decade, several new technologies have been introduced 
to the ﬁeld of bronchoscopy. Among them, the electromagnetic naviga-
tion systems have been approved by regulatory organizations and are 
now available. As experience with these technologies has increased, 
the body of published literature has grown. In this review we assess the 
most important and interesting articles in the ﬁeld.
Electromagnetic navigation
More than 150,000 solitary pulmonary nodules are reported each year 
in the United States (1). As the popularity of CT scan use for screen-
ing grows, these numbers are likely to increase substantially (2). More 
than 6.5 million CT scans of the chest were performed in the United 
states alone in 2001, highlighting the potential for this clinical situation. 
Detecting a nodule on either a chest radiograph or a CTscan frequently 
leads to a cascade of further investigations to establish a deﬁnite diagno-
sis. Performing thoracic surgery to obtain a tissue diagnosis is a frequent 
clinical scenario and, unfortunately, surgery is frequently performed 
for what turns out to be benign abnormalities. Conventional ﬂexible 
bronchoscopy, one of the least invasive chest procedures, is of limited 
value for obtaining a tissue diagnosis when such lesions are located in 
the peripheral segments of the lung. Historically, the diagnostic yield is 
speciﬁcally compromised if the lesion is less than 2 cm (3, 4). Flex-
ible bronchoscopy is limited mainly because of difﬁculties in reaching 
peripheral lesions with the ﬂexible endobronchial accessories, and local-
izing the lesion precisely under ﬂuoroscopy is frequently difﬁcult. Addi-
tionally, instruments currently used with a ﬂexible bronchoscope are not 
actively steerable but must be advanced in a ‘hit-or-miss’ fashion.
If issues of diagnostic yield could be resolved, ﬂexible bronchoscopy 
would represent a very interesting part in the workup and management 
of lung lesions. What are needed, therefore, are new methods for navi-
gation and localization, independent of visualization by ﬂuoroscopy 
and the technical skills of the bronchoscopist. A promising new tech-
nology is electromagnetic navigation based on virtual bronchoscopy 
and real-time three-dimensional CT scans.
Instrument
The electromagnetic navigation system is a localization device that as-
sists in placing endobronchial accessories (e.g., forceps, brush, needle) 
in the desired areas of the lung. The system uses low-frequency elec-
tromagnetic waves, which are emitted from an electromagnetic board 
placed under the bronchoscopy table mattress. A 1 mm diameter,
8 mm-long sensor probe mounted on the tip of a ﬂexible metal cable 
constitutes the main assembly of the device (locatable guide). Once the 
probe is placed within the electromagnetic ﬁeld, its position in the X, Y, 
and Z planes, as well as its orientation (roll, pitch, and yaw movements) 
are captured by the electromagnetic navigation system. This informa-
tion is then displayed on a monitor in real time. The locatable guide 
also has an added feature that allows its distal section to be steered 
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360°. The fully retractable probe is incorporated into a ﬂexible catheter 
(serving as an extended working channel), which, once placed in the 
desired location, creates an easy acces for bronchoscopic accessories. 
The computer software and monitor allow the bronchoscopist to view 
the reconstructed three-dimensional CTscans of the object’s anatomy in 
coronal, sagittal, and axial views together with superimposed graphic 
information depicting the position of the sensor probe.
Publications
Schwarz et al. [5] performed a trial to determine the practicality, ac-
curacy, and safety of real-time electromagnetic navigation in locating 
artiﬁcially created peripheral lung lesions in a swine model. Peripheral 
lung lesions were created in four swine models by inserting a metal 
tube via a transthoracic approach. A position sensor incorporated into 
the distal tip of a dedicated tool was used to navigate to the various 
target lesions. Information gathered in real time during bronchoscopy 
was presented on a monitor that simultaneously displayed previously 
acquired CT scans. When the target lesion was reached, biopsies were 
performed and the functionality and safety of the system were assessed 
and documented. The study showed a registration accuracy of 4.5 
mm on average. No adverse effects, such as pneumothorax or internal 
bleeding, were encountered in any animal in this study. Schwarz et al. 
[12] concluded that real-time electromagnetic positioning technology, 
coupled with previously acquired CT scans, is an accurate technology 
that can augment standard bronchoscopy to assist in reaching periph-
eral lung lesions and performing biopsies.
Based on the results of Schwarz et al. (5), Becker et al. (6) performed 
a pilot study in humans. They examined the utility of the system in 
30 consecutive patients presenting for endoscopic evaluation of lung 
nodules and masses. The lesion size in this population varied from 12 
mm to 106 mm but was speciﬁcally not controlled for in this early trial. 
Evaluation was possible in 29 patients, and in 20 patients a deﬁnitive 
diagnosis was established, with no complications related to the naviga-
tion device.
The accuracy of ENB navigation has been proven in animal studies6 
and against ﬂuoroscopically veriﬁed reference points in humans.7 
Nevertheless, all preceding diagnostic studies utilizing ENB also used 
ﬂuoroscopy to guide biopsies. The role of ENB as a stand-alone tech-
nology is still unproven and concerns remain that biopsy instruments 
may dislodge an accurately positioned EWC when replacing the sensor 
probe. Eberhardt et al. (7) examine the yield of ENB without ﬂuoros-
copy in the diagnosis of peripheral lung lesions and solitary pulmonary 
nodules. Ninety-two peripheral lung lesions were biopsied in the 89 
subjects. The diagnostic yield of ENB was 67%, which was indepen-
dent of lesion size. The mean navigation error was 9 ± 6 mm; range 1 
to 31. When analyzed by lobar distribution, there was a trend towards a 
higher ENB yield in diagnosing lesions in the right middle lobe (88%). 
Eberhardt concluded, that ENB can be used as a stand-alone broncho-
scopic technique without compromising diagnostic yield or increasing 
pneumothorax risk. This may result in sizable timesaving and avoids 
radiation exposure.
Marquette et al. (8) conﬁrmed this results. In 40 patients all target le-
sions but one was reached and the overall diagnostic yield was 62.5% 
(25/40). Also the French group summarized, that Electromagnetic navi-
gation guided bronchoscopy has the potential to improve the diagnostic 
yield of transbronchial biopsies without additional ﬂuoroscopic guid-
ance and may be useful in early diagnosis of lung cancer, particularly in 
nonoperable patients.
Endobronchial ultrasound (EBUS) and electromagnetic navigation 
bronchoscopy (ENB) have increased the yield of ﬂexible bronchos-
copy in the diagnosis of peripheral lung lesions and solitary pulmonary 
nodules. Diagnostic yields for EBUS using a radial probe have been 
reported to be 58.3 to 80% 3,4,5,6,7,8,9 while ENB has reported yields 
of 69 to 74% 10,11,12. The yields of both these procedures are inde-
pendent of lesion size. EBUS enables direct visualization of the target 
lesion before attempting biopsy. However, EBUS lacks a navigation 
system and requires the operator to maneuver the bronchoscope blindly 
to the lesion with the knowledge of prior radiological investigations 
like Computer Tomography (CT) scans.
Biopsies using ENB have not always resulted in a diagnosis despite 
accurate navigation in the vast majority of cases to within 10 mm 
of the target center10-12. Respiratory variations causing larger than 
anticipated navigation errors10 and dislodgement of the EWC when 
biopsy instruments were introduced12 may account for this lower than 
expected diagnostic yield. ENB lacks a means to directly visualize 
lesions before biopsy. The role of combining EBUS with ENB to gain 
the beneﬁts and minimize the limitations of either technique has never 
been reported. Eberhardt et al. () performed a prospective randomized 
controlled trial comprising three arms with EBUS only, ENB only, and 
combined EBUS/ENB to test this hypothesis.
Of the 120 patients recruited, 118 had a deﬁnitive histological diag-
nosis and were included in the ﬁnal analysis. The diagnostic yield of 
the combined procedure (88%) was greater than either endobronchial 
ultrasound (69%) or electromagnetic navigation alone (59%; p=0.02). 
The group concluded, that combined endobronchial ultrasound and 
electromagnetic navigation improves the diagnostic yield of ﬂexible 
bronchoscopy in peripheral lung lesions without compromising safety.
Conclusion
Electromagnetic guidance can be performed safely in humans and can 
easily be incorporated into a ﬂexible bronchoscopy practice. Coupled 
with a new generation of steerable instruments, a much more reliable 
means of approaching peripheral lung lesions endoscopically ﬁnally
seems within reach. Such systems would not only provide a reliable 
means of establishing a tissue diagnosis, but would also open the door 
for endoscopic therapeutic management
in select patients. Even though the technology seems very attractive 
and pilot data are extremely encouraging, more studies establishing 
yield and best utility are needed.
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Surgery is the main curative treatment for early stage NSCLC. Never-
theless, more than 50 % of patients die of tumor progression after com-
plete surgical resection. Recurrence occurs outside the chest in about 
two third of cases and deserves the use of adjuvant treatments.
In the early 90’s, the Medical Research Council and Institut Gustave-
Roussy performed a large overview on the role of chemotherapy in 
NSCLC using updated individual data. A 13% reduction in the risk of 
death was observed, suggesting an absolute beneﬁt of 5% with adjuvant 
chemotherapy at 5 years (p=0.08). Sex, performance status, age and 
histologic subtype had no impact on this effect. These results consti-
tuted the rationale for a new generation of randomized studies with 
platin-based regimens.
A North American Intergroup Trial (Int 0115) demonstrated that a 
combination of 4 cycles of chemotherapy (etoposide-cisplatin) plus 
concomitant thoracic radiotherapy was not superior to radiotherapy 
alone given at the same dose in 463 patients with resected stage II and 
IIIA NSCLC. Additionally, there was no impact of the p53 and k-ras 
modiﬁcations on the outcome of patients. 
In the ALPI trial, patients with resected stage I-IIIa NSCLC were 
randomly allocated to receive either 3 courses of MVP (Mitomycin 8 
mg/m2 day 1; Vindesine 3mg/m2 day 1 and 8; Cisplatin 100 mg/m2 day 
1 every 3 weeks for 3 cycles) or no adjuvant treatment after complete 
resection. Overall 1209 patients were enrolled into the study, 606 in 
the chemotherapy arm and 603 in the control arm. In the chemotherapy 
arm, 69% of patients completed the treatment but half of them had trea-
ment modiﬁcations. Radiotherapy was delivered in 482 patients. A total 
of 1088 patients were analysed with a median follow-up of 63 months. 
H.R. was 0.94 for overall survival and 0.89 for disease-free survival. 
No statistically signiﬁcant difference was observed even if the differ-
ence was borderline signiﬁcant for stage II disease.
The IALT was a large worldwide randomized study whose aim was to 
determine the impact on overall survival of 3 to 4 cycles of a cisplatin-
based chemotherapy (CT) regimen after complete surgical resection in 
patients with stage I-III NSCLC. Thoracic radiotherapy might be given 
according to the preregistration policy of each centre. There were 932 
pts allocated to CT and 67% received at least 300 mg/m2 of cisplatin. 
The drug combined with cisplatin was etoposide (56%), vinorelbine 
(27%), vinblastine (11%) and vindesine (6%). There were 935 pts in 
the control arm. After a median follow-up of 56 months, overall sur-
vival was signiﬁcantly different between the 2 arms: 2 and 5-yr survival 
rates were 70% and 45 % in the CT arm vs 67% and 40% in the control 
arm respectively (RR=0.86 [0.76-0.98], p<0.03). Disease-free survival 
was also signiﬁcantly different: 61 % and 39% in the CT arm vs 55% 
and 34% in the control arm at 2 and 5 yrs respectively (RR=0.83 [0.74-
0.94], p<0.003). No signiﬁcant interaction was observed with age, 
gender, PS, type of surgery, pStage, histology, cisplatin dose, combined 
drug, radiotherapy. ERCC1 was immunohistochemically evaluated 
in 761 tumor specimens of patients. ERCC1 expression was positive 
in 44% and negative in 56%. A beneﬁt from cisplatin-based adjuvant 
chemotherapy was associated with the negative expression of ERCC1 
(test for interaction, p=0.009)
In the post-operative subgroup of the Big Lung Trial, no beneﬁt from 
adjuvant chemotherapy was observed among 381 patients but the popu-
lation was not heterogeneous in particular concerning the quality of the 
resection, and the compliance to chemotherapy was poor.
A Japanese randomized study compared adjuvant UFT for 2 years to no 
treatment in patients with completely resected stage I NSCLC. Among 
979 eligible patients, there was a signiﬁcant advantage in favor of UFT 
(p=0.036) but the beneﬁt was restricted to the 27% of patients with 
T2N0 NSCLC. At the 2004 ASCO meeting, the Japanese adjuvant UFT 
meta-analysis conﬁrmed a signiﬁcant advantage of the drug compared 
to control in 2003 patients (p<0.001).
The NCI-Canada conducted a phase III trial (JBR 10) comparing sur-
gery alone to surgery followed by adjuvant chemotherapy with cisplatin 
and vinorelbine in 459 eligible patients with stage Ib and II resected 
NSCLC. They showed a 15% beneﬁt at 5 years (p=0.012). The beneﬁt 
was restricted to stage II patients.
The CALGB also conducted a randomized trial in 344 patients with 
stage Ib NSCLC (CALGB 9633). The initial beneﬁt at 4 years reported 
with adjuvant Paclitaxel-Carboplatin compared to no adjuvant treat-
ment was not conﬁrmed with a longer follow-up and the beneﬁt is only 
3% at 5 years (p=0.10).
In the ANITA 1 trial, which also concerned patients with completely re-
sected NSCLC, chemotherapy consisted of 4 cycles of cisplatin at 100 
mg/m2 every 4 weeks and 16 cycles of vinorelbine at 30 mg/m2 weekly 
compared to a control arm. A total of 831 patients were included from 
October 1994 to December 2000. There were 35% stage I, 30% stage II 
and 35% stage III. Again, there was a survival advantage for adjuvant 
chemotherapy. Survival rates were 68%, 51%and 45% at 2, 5 and 7 
years in the chemotherapy arm vs 63%, 43% and 37% respectively. RR 
was 0.80 [0.66-0.96] with a p value of 0.017.
The LACE meta-analysis reported at ASCO 2006 included a total of 
4584 patients accrued in the 5 recent cisplatin-based adjuvant trials. It 
conﬁrmed the beneﬁt of adjuvant chemotherapy with a 5.3% improve-
ment of survival at 5 years (p=0.0043). Disease-free survival was also 
improved (5.2% at 5 years, p<0.0001).
